Crossmark

Combination intravitreal anti-vascular endothelial growth factor inhibitors and macular laser photocoagulation relative to intravitreal injection monotherapy in macular oedema secondary to retinal vein occlusion: a meta-analysis of randomized controlled trials

Crossref DOI link: https://doi.org/10.1038/s41433-021-01833-2

Published Online: 2021-11-24

Published Print: 2022-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Bhambra, Nishaant http://orcid.org/0000-0003-4966-6578
Sayal, Aman P. http://orcid.org/0000-0002-8045-2247
Popovic, Marko M. http://orcid.org/0000-0002-0370-5968
Muni, Rajeev H.

Kertes, Peter J.
License Information

Text and Data Mining valid from 2021-11-24

Version of Record valid from 2021-11-24
More Information

Article History

Received: 22 May 2021

Revised: 5 October 2021

Accepted: 21 October 2021

First Online: 24 November 2021

Competing interests

: MMP: Financial Support (to institution)—PSI Foundation. PJK: Advisory board—Novartis, Alcon, Bayer Roche, Novelty Nobility; Financial support (to institution)—Bayer, Roche, Novartis; Financial support—Novartis, Bayer; Equity owner—ArcticDx. RHM: Advisory board— Bayer, Novartis, Allergan, Roche; Financial Support (to institution)—Bayer, Novartis.

Document is current

Any future updates will be listed below